Alnylam Pharmaceuticals | ALNY - Sales Revenues


Alnylam Pharmaceuticals reported $1.1B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Moderna USD 678M 342M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 14.36B 478M Sep/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 12.2B 3.19B Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Takeda JPY 1.19T 80B Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025